ID   Jurkat E6.1
AC   CVCL_0367
AS   CVCL_4530
SY   JurkatE6-1; Jurkat E6-1; Jurkat, Clone E6-1; Jurkat Clone E6-1; Jurkat (clone E6-1); JURKAT E-6.1; JURKAT E-61; Jurkat-CloneE61; Jurkat-E6; Jurkat E6; J.E6-1; E6-1; Jurkat J6
DR   BTO; BTO:0001948
DR   CLO; CLO_0007044
DR   CLO; CLO_0007045
DR   MCCL; MCC:0000260
DR   CLDB; cl2962
DR   CLDB; cl5213
DR   ArrayExpress; E-MTAB-2706
DR   ATCC; TIB-152
DR   BCRC; 60424
DR   BCRJ; 0125
DR   BioSample; SAMN03472194
DR   cancercelllines; CVCL_0367
DR   CCRID; 1101HUM-PUMC000075
DR   CCRID; 1101HUM-PUMC000348
DR   CCRID; 1102HUM-NIFDC00049
DR   CCRID; 4201HUM-CCTCC00094
DR   Cell_Model_Passport; SIDM01244
DR   ChEMBL-Cells; CHEMBL4295390
DR   ChEMBL-Targets; CHEMBL4296446
DR   CLS; 300223
DR   Cosmic; 913419
DR   ECACC; 88042803
DR   EGA; EGAS00001000610
DR   GEO; GSE101101
DR   GEO; GSM472928
DR   GEO; GSM510511
DR   GEO; GSM827151
DR   GEO; GSM923424
DR   GEO; GSM945267
DR   GEO; GSM945268
DR   HIVReagentProgram; ARP-177
DR   KCB; KCB 94008YJ
DR   KCLB; 40152
DR   MetaboLights; MTBLS789
DR   NCBI_Iran; C121
DR   PharmacoDB; Jurkat_Clone_E61_713_2019
DR   PRIDE; PRD000345
DR   PRIDE; PXD000148
DR   PRIDE; PXD000589
DR   PRIDE; PXD002871
DR   PRIDE; PXD004415
DR   PRIDE; PXD010176
DR   PRIDE; PXD032302
DR   Progenetix; CVCL_0367
DR   PubChem_Cell_line; CVCL_0367
DR   TOKU-E; 2081
DR   Ubigene; YC-D012
DR   Wikidata; Q54899132
DR   Wikidata; Q54899133
RX   PubMed=7592872;
RX   PubMed=8316623;
RX   PubMed=9707173;
RX   PubMed=10468210;
RX   PubMed=10832058;
RX   PubMed=11416159;
RX   PubMed=11481229;
RX   PubMed=11669127;
RX   PubMed=15472075;
RX   PubMed=18842727;
RX   PubMed=20215515;
RX   PubMed=23933134;
RX   PubMed=25485619;
RX   PubMed=25877200;
RX   PubMed=25894527;
RX   PubMed=26546556;
RX   PubMed=26589293;
RX   PubMed=28464451;
RX   PubMed=29739316;
RX   PubMed=32938764;
CC   Group: Space-flown cell line (cellonaut).
CC   Part of: Tumor Immunology Bank (TIB) collection from Salk (transferred to ATCC in 1981).
CC   Population: Caucasian.
CC   Doubling time: 20.7 +- 2.2 hours (PubMed=10468210).
CC   HLA typing: A*03:01,03:01; B*07:02,35:03; C*04:01,07:02 (PubMed=26589293).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Argfs*19 (c.121delG); ClinVar=VCV000009512; Zygosity=Heterozygous (PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 959; BAX; Simple; p.Glu41Glyfs*33 (c.121dupG); ClinVar=VCV000009511; Zygosity=Heterozygous (PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 16712; FBXW7; Simple; p.Arg505Cys (c.1513C>T); ClinVar=VCV000069961; Zygosity=Heterozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; p.Gln345Ter (c.1033C>T); Zygosity=Heterozygous (PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 6079; INPP5D; Simple; c.1097+1065_1097+1112del47; Zygosity=Heterozygous (PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 7325; MSH2; Simple; p.Arg711Ter (c.2131C>T); ClinVar=VCV000090903; Zygosity=Homozygous (PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 7329; MSH6; Simple; p.Phe1088Serfs*2 (c.3261delC); ClinVar=VCV000089363; Zygosity=Homozygous (from parent cell line).
CC   Sequence variation: Mutation; HGNC; 11491; SYK; Simple; p.Met34Hisfs*3 (c.98_99insG); Zygosity=Heterozygous (PubMed=7592872; PubMed=29739316).
CC   Sequence variation: Mutation; HGNC; 11998; TP53; Simple; p.Arg196Ter (c.586C>T); ClinVar=VCV000043589; Zygosity=Heterozygous (PubMed=29739316).
CC   Omics: Cell surface proteome.
CC   Omics: Deep phosphoproteome analysis.
CC   Omics: Deep quantitative phosphoproteome analysis.
CC   Omics: Genome sequenced.
CC   Omics: H3K4me3 ChIP-seq epigenome analysis.
CC   Omics: SNP array analysis.
CC   Omics: Transcriptome analysis by RNAseq.
CC   Anecdotal: Have been flown in space on shuttle flights STS-76, STS-80 and STS-95 to study apoptosis and cytoskeleton modifications (PubMed=9707173; PubMed=10832058; PubMed=11481229; PubMed=11669127).
CC   Derived from site: In situ; Peripheral blood; UBERON=UBERON_0000178.
CC   Cell type: T-cell; CL=CL_0000084.
ST   Source(s): ATCC; CCRID; CLS; ECACC; KCLB; PubMed=11416159; PubMed=25877200; PubMed=32938764
ST   Amelogenin: X,Y
ST   CSF1PO: 10,11,12,13 (PubMed=32938764)
ST   CSF1PO: 11,12 (ATCC; CCRID; CLS; ECACC; KCLB; PubMed=25877200)
ST   D13S317: 8,12
ST   D16S539: 11
ST   D18S51: 12,13,20,21 (PubMed=32938764)
ST   D18S51: 13,21 (CCRID; CLS; PubMed=11416159; PubMed=25877200)
ST   D19S433: 14,15.2
ST   D21S11: 30.2,31.2,33.2 (PubMed=32938764)
ST   D21S11: 31.2,33.2 (CCRID; CLS; PubMed=11416159; PubMed=25877200)
ST   D2S1338: 19,23
ST   D3S1358: 15 (CCRID; KCLB)
ST   D3S1358: 15,17 (CLS; PubMed=25877200; PubMed=32938764)
ST   D5S818: 9
ST   D7S820: 8,10 (CLS; ECACC)
ST   D7S820: 8,12 (ATCC; CCRID; KCLB; PubMed=25877200; PubMed=32938764)
ST   D8S1179: 12,13,14,15 (PubMed=32938764)
ST   D8S1179: 13,14 (CCRID; PubMed=11416159; PubMed=25877200)
ST   FGA: 20,21
ST   Penta D: 11,13
ST   Penta E: 10,12
ST   TH01: 6,9.3
ST   TPOX: 8,10
ST   vWA: 18 (ATCC; CCRID; CLS; ECACC; KCLB; PubMed=11416159; PubMed=25877200)
ST   vWA: 18,19 (PubMed=32938764)
DI   NCIt; C7953; Childhood T acute lymphoblastic leukemia
DI   ORDO; Orphanet_99861; Precursor T-cell acute lymphoblastic leukemia
OX   NCBI_TaxID=9606; ! Homo sapiens (Human)
HI   CVCL_0065 ! Jurkat
SX   Male
AG   14Y
CA   Cancer cell line
DT   Created: 04-04-12; Last updated: 05-10-23; Version: 39
RX   PubMed=7592872; DOI=10.1074/jbc.270.44.26533;
RA   Fargnoli J., Burkhardt A.L., Laverty M., Kut S.A., van Oers N.S.C.,
RA   Weiss A., Bolen J.B.;
RT   "Syk mutation in Jurkat E6-derived clones results in lack of p72syk
RT   expression.";
RL   J. Biol. Chem. 270:26533-26537(1995).
RX   PubMed=8316623; DOI=10.2307/3578190;
RA   Evans H.H., Ricanati M., Horng M.-F., Jiang Q.-Y., Mencl J.,
RA   Olive P.L.;
RT   "DNA double-strand break rejoining deficiency in TK6 and other human
RT   B-lymphoblast cell lines.";
RL   Radiat. Res. 134:307-315(1993).
RX   PubMed=9707173; DOI=10.1096/fasebj.12.11.1007;
RA   Lewis M.L., Reynolds J.L., Cubano L.A., Hatton J.P., Lawless B.D.,
RA   Piepmeier E.H.;
RT   "Spaceflight alters microtubules and increases apoptosis in human
RT   lymphocytes (Jurkat).";
RL   FASEB J. 12:1007-1018(1998).
RX   PubMed=10468210; DOI=10.1016/S0891-5849(99)00074-X;
RA   Schoene N.W., Kamara K.S.;
RT   "Population doubling time, phosphatase activity, and hydrogen peroxide
RT   generation in Jurkat cells.";
RL   Free Radic. Biol. Med. 27:364-369(1999).
RX   PubMed=10832058; DOI=10.1016/S0531-5565(00)00090-5;
RA   Cubano L.A., Lewis M.L.;
RT   "Fas/APO-1 protein is increased in spaceflown lymphocytes (Jurkat).";
RL   Exp. Gerontol. 35:389-400(2000).
RX   PubMed=11416159; DOI=10.1073/pnas.121616198;
RA   Masters J.R.W., Thomson J.A., Daly-Burns B., Reid Y.A., Dirks W.G.,
RA   Packer P., Toji L.H., Ohno T., Tanabe H., Arlett C.F., Kelland L.R.,
RA   Harrison M., Virmani A.K., Ward T.H., Ayres K.L., Debenham P.G.;
RT   "Short tandem repeat profiling provides an international reference
RT   standard for human cell lines.";
RL   Proc. Natl. Acad. Sci. U.S.A. 98:8012-8017(2001).
RX   PubMed=11481229; DOI=10.1096/fj.00-0820fje;
RA   Lewis M.L., Cubano L.A., Zhao B.-T., Dinh H.-K., Pabalan J.G.,
RA   Piepmeier E.H., Bowman P.D.;
RT   "cDNA microarray reveals altered cytoskeletal gene expression in
RT   space-flown leukemic T lymphocytes (Jurkat).";
RL   FASEB J. 15:1783-1785(2001).
RX   PubMed=11669127; DOI=10.1016/S0094-5765(01)00116-3;
RA   Schatten H., Lewis M.L., Chakrabarti A.;
RT   "Spaceflight and clinorotation cause cytoskeleton and mitochondria
RT   changes and increases in apoptosis in cultured cells.";
RL   Acta Astronaut. 49:399-418(2001).
RX   PubMed=15472075; DOI=10.1126/science.1102160;
RA   Weng A.P., Ferrando A.A., Lee W., Morris J.P. IV, Silverman L.B.,
RA   Sanchez-Irizarry C., Blacklow S.C., Look A.T., Aster J.C.;
RT   "Activating mutations of NOTCH1 in human T cell acute lymphoblastic
RT   leukemia.";
RL   Science 306:269-271(2004).
RX   PubMed=18842727; DOI=10.1128/JVI.01726-08;
RA   Takeuchi Y., McClure M.O., Pizzato M.;
RT   "Identification of gammaretroviruses constitutively released from cell
RT   lines used for human immunodeficiency virus research.";
RL   J. Virol. 82:12585-12588(2008).
RX   PubMed=20215515; DOI=10.1158/0008-5472.CAN-09-3458;
RA   Rothenberg S.M., Mohapatra G., Rivera M.N., Winokur D., Greninger P.,
RA   Nitta M., Sadow P.M., Sooriyakumar G., Brannigan B.W., Ulman M.J.,
RA   Perera R.M., Wang R., Tam A., Ma X.-J., Erlander M., Sgroi D.C.,
RA   Rocco J.W., Lingen M.W., Cohen E.E.W., Louis D.N., Settleman J.,
RA   Haber D.A.;
RT   "A genome-wide screen for microdeletions reveals disruption of
RT   polarity complex genes in diverse human cancers.";
RL   Cancer Res. 70:2158-2164(2010).
RX   PubMed=23933134; DOI=10.1016/j.jprot.2013.07.019;
RA   Storvold G.L., Landskron J., Strozynski M., Arntzen M.O.,
RA   Koehler C.J., Kalland M.E., Tasken K., Thiede B.;
RT   "Quantitative profiling of tyrosine phosphorylation revealed changes
RT   in the activity of the T cell receptor signaling pathway upon
RT   cisplatin-induced apoptosis.";
RL   J. Proteomics 91:344-357(2013).
RX   PubMed=25485619; DOI=10.1038/nbt.3080;
RA   Klijn C., Durinck S., Stawiski E.W., Haverty P.M., Jiang Z.-S.,
RA   Liu H.-B., Degenhardt J., Mayba O., Gnad F., Liu J.-F., Pau G.,
RA   Reeder J., Cao Y., Mukhyala K., Selvaraj S.K., Yu M.-M., Zynda G.J.,
RA   Brauer M.J., Wu T.D., Gentleman R.C., Manning G., Yauch R.L.,
RA   Bourgon R., Stokoe D., Modrusan Z., Neve R.M., de Sauvage F.J.,
RA   Settleman J., Seshagiri S., Zhang Z.-M.;
RT   "A comprehensive transcriptional portrait of human cancer cell
RT   lines.";
RL   Nat. Biotechnol. 33:306-312(2015).
RX   PubMed=25877200; DOI=10.1038/nature14397;
RA   Yu M., Selvaraj S.K., Liang-Chu M.M.Y., Aghajani S., Busse M.,
RA   Yuan J., Lee G., Peale F.V., Klijn C., Bourgon R., Kaminker J.S.,
RA   Neve R.M.;
RT   "A resource for cell line authentication, annotation and quality
RT   control.";
RL   Nature 520:307-311(2015).
RX   PubMed=25894527; DOI=10.1371/journal.pone.0121314;
RA   Bausch-Fluck D., Hofmann A., Bock T., Frei A.P., Cerciello F.,
RA   Jacobs A., Moest H., Omasits U., Gundry R.L., Yoon C., Schiess R.,
RA   Schmidt A., Mirkowska P., Hartlova A.S., Van Eyk J.E., Bourquin J.-P.,
RA   Aebersold R., Boheler K.R., Zandstra P.W., Wollscheid B.;
RT   "A mass spectrometric-derived cell surface protein atlas.";
RL   PLoS ONE 10:E0121314-E0121314(2015).
RX   PubMed=26546556; DOI=10.1016/j.jprot.2015.10.029;
RA   Nguyen T.D., Carrascal M., Vidal-Cortes O., Gallardo O., Casas V.,
RA   Gay M., Phan V.C., Abian J.;
RT   "The phosphoproteome of human Jurkat T cell clones upon costimulation
RT   with anti-CD3/anti-CD28 antibodies.";
RL   J. Proteomics 131:190-198(2016).
RX   PubMed=26589293; DOI=10.1186/s13073-015-0240-5;
RA   Scholtalbers J., Boegel S., Bukur T., Byl M., Goerges S., Sorn P.,
RA   Loewer M., Sahin U., Castle J.C.;
RT   "TCLP: an online cancer cell line catalogue integrating HLA type,
RT   predicted neo-epitopes, virus and gene expression.";
RL   Genome Med. 7:118.1-118.7(2015).
RX   PubMed=28464451; DOI=10.1002/pmic.201600470;
RA   Tran T.T., Strozynski M., Thiede B.;
RT   "Quantitative phosphoproteome analysis of cisplatin-induced apoptosis
RT   in Jurkat T cells.";
RL   Proteomics 17:1600470.1-1600470.11(2017).
RX   PubMed=29739316; DOI=10.1186/s12864-018-4718-6;
RA   Gioia L., Siddique A., Head S.R., Salomon D.R., Su A.I.;
RT   "A genome-wide survey of mutations in the Jurkat cell line.";
RL   BMC Genomics 19:334.1-334.13(2018).
RX   PubMed=32938764; DOI=10.1128/JVI.01334-20;
RA   Fernandez M.V., Hoffman H.K., Pezeshkian N., Tedbury P.R.,
RA   van Engelenburg S.B., Freed E.O.;
RT   "Elucidating the basis for permissivity of the MT-4 T-cell line to
RT   replication of an HIV-1 mutant lacking the gp41 cytoplasmic tail.";
RL   J. Virol. 94:e01334.20.1-e01334.20.27(2020).